Rothschild & Co Asset Management US’s Iovance Biotherapeutics IOVA Stock Holding History

Rothschild & Co Asset Management US’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$2.68M	Sell	418,929 -31,948	-7%	-$249K	0.04%	218
2022 Q3	$4.32M	Sell	450,877 -33,145	-7%	-$382K	0.07%	192
2022 Q2	$5.34M	Sell	484,022 -24,673	-5%	-$323K	0.08%	172
2022 Q1	$8.47M	Sell	508,695 -120,918	-19%	-$1.87M	0.11%	155
2021 Q4	$12M	Buy	629,613 +95,526	+18%	+$2.1M	0.14%	161
2021 Q3	$13.2M	Sell	534,087 -59,667	-10%	-$1.41M	0.16%	151
2021 Q2	$15.4M	Buy	593,754 +75,218	+15%	+$1.96M	0.18%	148
2021 Q1	$16.4M	Sell	518,536 -244,887	-32%	-$10.2M	0.2%	143
2020 Q4	$35.4M	Sell	763,423 -145,864	-16%	-$5.79M	0.46%	60
2020 Q3	$29.9M	Sell	909,287 -54,597	-6%	-$1.67M	0.54%	55
2020 Q2	$26.5M	Buy	963,884 +47,175	+5%	+$1.55M	0.39%	95
2020 Q1	$27.4M	Buy	916,709 +640,349	+232%	+$17M	0.43%	87
2019 Q4	$7.65M	Buy	+276,360	New	+$6.29M	0.08%	268

Other funds holding IOVA

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rothschild & Co Asset Management US's IOVA Position: Q4 2022 in Review

Rothschild & Co Asset Management US reduced its Iovance Biotherapeutics (IOVA) stake by 7.1% in Q4 2022, selling an estimated $249K and leaving 418,929 shares worth $2.68M. The position accounts for 0.04% of the portfolio, ranked #218.

Rothschild & Co Asset Management US first reported a position in IOVA in Q4 2019 and has held it in 13 quarters since. The position peaked at $35.4M in Q4 2020. 218 funds tracked by Wall St. Rank hold IOVA as of Q4 2022.

Rothschild & Co Asset Management US held 418,929 shares of Iovance Biotherapeutics worth $2.68M as of Q4 2022.
Rothschild & Co Asset Management US sold 31,948 Iovance Biotherapeutics shares in Q4 2022, an estimated $249K.
Iovance Biotherapeutics made up 0.04% of Rothschild & Co Asset Management US's portfolio in Q4 2022, its #218 holding.
Rothschild & Co Asset Management US first reported a position in Iovance Biotherapeutics in Q4 2019 and has held it in 13 quarters since.
Rothschild & Co Asset Management US's Iovance Biotherapeutics position peaked at $35.4M in Q4 2020.
218 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2022.

Based on Rothschild & Co Asset Management US's 13F filing for Q4 2022, filed 14 Feb 2023.